Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety

Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety

Background: Seroconversion and longevity of vaccine-induced immune response is blunted in immune-mediated inflammatory disease (IMID) patients owing to immunosuppressive regimens. COVID-19 booster vaccines after a primary series have been proposed with inconclusive evidence on efficacy to date. Meth...

Full description

Bibliographic Details
Main Authors:	Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Sen Hee Tay
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Vaccines
Subjects:	COVID-19 COVID-19 vaccines immune-mediated inflammatory diseases autoimmune diseases antirheumatic agents rituximab
Online Access:	https://www.mdpi.com/2076-393X/10/5/668

Similar Items

Coronavirus disease 2019 in patients with rheumatic immune-mediated diseases in a single University Hospital, matched case-control study and literature review
by: David Martínez-López, et al.
Published: (2022-12-01)

Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases
by: Maria De Santis, et al.
Published: (2022-05-01)

Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry
by: María del Mar Ayala Gutiérrez, et al.
Published: (2021-04-01)

Profile of Patients with Rheumatoid Arthritis: a Descriptive Analysis
by: Junior Garcia de Oliveira, et al.
Published: (2022-10-01)

B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)
by: E. L. Nasonov, et al.
Published: (2021-09-01)

Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
by: Federica Filippini, et al.
Published: (2023-06-01)

ANTI-B-CELL THERAPY AT IMMUNE INFLAMMATORY RHEUMATIC DISEASES: EFFICACY AND TOLERABILITY IN 229 PATIENTS
by: L. P. Ananieva, et al.
Published: (2014-10-01)

CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases
by: Kevin Chevalier, et al.
Published: (2023-03-01)

Rituximab and COVID-19 infection in patients with autoimmune rheumatic diseases – A real-world study from India
by: Aswin M Nair, et al.
Published: (2023-01-01)

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
by: John Tesser, et al.
Published: (2023-11-01)

Efficacy and Safety of Rituximab in Autoimmune Disease—Associated Interstitial Lung Disease: A Prospective Cohort Study
by: Natalia Mena-Vázquez, et al.
Published: (2022-02-01)

Coronavirus disease 2019 (COVID-19) and autoimmunity
by: E. L. Nasonov
Published: (2021-03-01)

Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies
by: Xueyi Huang, et al.
Published: (2022-07-01)

Autoimmune Hemolytic Anemia: A Late Presentation of Post-COVID-19 Syndrome
by: Emad Al Khoufi, et al.
Published: (2023-01-01)

Covid-19 infection in patients with autoimmune rheumatic diseases: Patient’s perspective and descriptive analysis from a lower-middle-income country
by: Mehmood Riaz, et al.
Published: (2023-09-01)

Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
by: Ruth Xian Lynn Yap, et al.
Published: (2024-03-01)

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
by: Koos P. J. van Dam, et al.
Published: (2023-05-01)

The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases
by: Yan Geng, et al.
Published: (2023-06-01)

Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
by: E. L. Nasonov, et al.
Published: (2021-12-01)

TREATMENT OF IgG4-RELATED DISEASE
by: E. V. Sokol, et al.
Published: (2016-07-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)

COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease
by: Wen Yanfang, et al.
Published: (2023-11-01)

Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study
by: Valeria Belleudi, et al.
Published: (2021-05-01)

Frequency and Effective Factors on Discontinuation of Treatment in Patients with Inflammatory Rheumatic Diseases
by: Maryam Mobini, et al.
Published: (2022-04-01)

Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity
by: E. L. Nasonov, et al.
Published: (2020-09-01)

COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review
by: Aline Pereira da Rocha, et al.
Published: (2020-12-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

Evaluation of SARS-CoV-2 Vaccine-Induced Antibody Responses in Patients with Neuroimmunological Disorders: A Real-World Experience
by: Hyunjin Ju, et al.
Published: (2024-02-01)

The role of extra-thymic AIRE-expressing cells (eTACs) in AIRE-propagated immune tolerance
by: Rosen, L
Published: (2021)

Clinical Course and Outcomes of COVID-19 Infection in Patients Treated with Rituximab: A Tertiary Care Center Experience
by: Alhowaish TS, et al.
Published: (2023-08-01)

Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
by: A. A. Akimova, et al.
Published: (2023-03-01)

Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy
by: Maximilian Töllner, et al.
Published: (2022-03-01)

Association between biologic therapy and fracture incidence in patients with selected rheumatic and autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials
by: Fang Lv, et al.
Published: (2022-07-01)

Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response
by: Aditi Mohan, et al.
Published: (2023-10-01)

Neutralizing Antibody Response, Safety, and Efficacy of mRNA COVID-19 Vaccines in Pediatric Patients with Inflammatory Bowel Disease: A Prospective Multicenter Case—Control Study
by: Kyung Jae Lee, et al.
Published: (2022-08-01)

Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study
by: Warren Fong, et al.
Published: (2023-08-01)

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review
by: Arvind Nune, et al.
Published: (2023-10-01)

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics
by: Valeria Conti, et al.
Published: (2020-12-01)

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA
by: T. V. Popkova, et al.
Published: (2016-07-01)

COVID-19 vaccine confidence in the post-vaccination era: Perceptions among adults with immune-mediated inflammatory diseases
by: F.M. Santana, et al.
Published: (2023-12-01)